Nextleaf, a Vancouver, B.C.-Based Company, owns one of the Largest Portfolios of U.S. Patents in the Industry (Benzinga).
As the United States federal government continues to look at the option of national cannabis legalization, there are now only two states which haven’t been given limited access. As a result of the U.S. government dragging its feet on federal legalization, large multinational companies are investing in Canadian licensed producer partnerships to understand cannabis and develop intellectual property to deploy in a federally legal system.
RELATED: IP Strategy And Cannabis: How Canada’s Nextleaf Is Monetizing Its Patents (Forbes)
Doing so will presumably give these companies a competitive advantage once cannabis is legal on a federal level in the United States. Since its inception, one Canadian company hyper-focused on this issue is Nextleaf Solutions (CSE:OILS)(OTCQB:OILFF), a Health Canada licensed processor and technology company obtaining patents at lightning speed for the extraction, distillation, and delivery of cannabinoids.
Nextleaf, a Vancouver, B.C.-based company, owns one of the largest portfolios of U.S. patents in the industry and just announced the launch of its Specialty Molecules Division to focus on developing and commercializing novel psychoactive compounds. The division is being fueled by the company’s existing intellectual property (IP) portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate.
The cannabis industry has seen an increased focus on novel cannabinoid-based products with wellness and therapeutic applications and investment from large pharmaceutical and consumer packaged goods (CPG) companies. An example is the recent $221 million investment by British American Tobacco (NYSE:BT) in Canadian cannabis producer Organigram (NASDAQ:OGI).
Learn more about Nextleaf at www.nextleafsolutions.com.
Read the full article on Benzinga
(Studying now..)
